ARTICLE | Company News
Metris, Plethora deal
July 3, 2006 7:00 AM UTC
Metris granted PLE an exclusive worldwide license to develop and market M5003 and M5004. Early next year, PLE expects M5003, a non-steroidal, anti-inflammatory compound, to start Phase IIb testing to ...